Showing results (41-50 of 65) with videos related to
Sort By:
Pageof 7
Pharmacological Research|February 8, 2023
Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasisRobert RoskoskiPharmacological Research|April 13, 2024
Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomasRobert RoskoskiBiochemical and Biophysical Research Communications|August 3, 2010
RAF protein-serine/threonine kinases: structure and regulationRobert RoskoskiPharmacological Research|March 17, 2019
Properties of FDA-approved small molecule protein kinase inhibitorsRobert RoskoskiPharmacological Research|April 19, 2025
Properties of FDA-approved small molecule protein kinase inhibitors: A 2025 updateRobert RoskoskiPharmacological Research|January 26, 2026
Properties of FDA-approved small molecule protein kinase inhibitors: a 2026 updateRobert RoskoskiPharmacological Research|December 4, 2012
Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibitionRobert RoskoskiPharmacological Research|May 10, 2012
ERK1/2 MAP kinases: structure, function, and regulationRobert RoskoskiBiochemical and Biophysical Research Communications|October 18, 2005
Structure and regulation of Kit protein-tyrosine kinase--the stem cell factor receptorRobert RoskoskiPharmacological Research|September 20, 2016
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasmsRobert RoskoskiPageof 7